Reports from University of Cincinnati advance knowledge in attention deficit hyperactivity disorder in children
2007 SEP 17 -- Researchers detail in "Atomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvement," new data in attention deficit hyperactivity disorder. "In children with attention deficit hyperactivity disorder (ADHD), clinical responses to the selective norepinephrine reuptake inhibitor atomoxetine (ATX) vary. We sought to determine in children with Tourette Syndrome (TS) whether clinical responses correlate with changes in short interval cortical inhibition (SICI)," investigators in the United States report. "Fourteen children, ages 8-16, with ADHD and TS were treated open-label with ATX for one month. ADHD rating scale scores and SICI, measured with paired-pulse transcranial magnetic stimulation (pTMS), were assessed blindly and independently at treatment onset and one month later. Eleven children, mean ADHD rating scale scores 31.8 (SD 8.2) at onset, completed the study. After one month, ADHDRS changes ranged from an increase of 4 points to a decrease (improvement) of 24 points (mean change -9.6, SD 9.1). The changes in ADHDRS scores correlated with reduction in SICI (r=.74, p=.010). In children with TS, one month of atomoxetine treatment appears to induce correlated improvements in ADHD and, paradoxically, further reductions in cortical inhibition. PTMS-evoked SICI in ADHD with TS may be a biomarker of both deficiency and compensatory changes within cortical interneuronal systems," wrote D.L. Gilbert and colleagues, University of Cincinnati. The researchers concluded: "Effective atomoxetine treatment may augment compensatory processes and thereby reduce SICI." Gilbert and colleagues published their study in Clinical Neurophysiology (Atomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvement. Clinical Neurophysiology, 2007;118(8):1835-41). For additional information, contact D.L. Gilbert, Cincinnati Children's Hospital Medical Center and The University of Cincinnati, Dept. of Neurology, Cincinnati Children's Hospital Medical Center and The University of Cincinnati, School of Medicine, OH 45229-3039 USA.. The publisher of the journal Clinical Neurophysiology can be contacted at: Elsevier Science Ireland Ltd., Customer Relations Manager, Bay 15, Shannon Industrial Estate, Co. Clare, Ireland. Keywords: United States, Antidepressant, Atomoxetine, Attention Deficit Hyperactivity Disorder, Central Nervous System Agent, Central Nervous System Disease, Clinical Neurophysiology, Developmental Disabilities, Tourette Syndrome. This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.
|
